Form 4: Pulmonx Director Receives Equity Grant

Director Thomas William Burns was granted 40,000 restricted stock units in Pulmonx Corporation.

Summary

• Director Thomas William Burns acquired 40,000 restricted stock units (RSUs) of Pulmonx Corporation common stock.
• The transaction occurred on June 5, 2026.
• The RSUs were granted at a price of $0 per share.
• Following this transaction, the director's total beneficial ownership is 113,399 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon vesting.

Risks

• Market volatility affecting the future value of the equity grant.

Future Outlook

The RSUs vest on the earlier of the one-year anniversary of the grant date (June 5, 2027) or the date of the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to incentivize long-term oversight and alignment with shareholder value in the medical device sector.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for publicly traded medical technology companies.
• Vesting schedules tied to annual meetings are common practice for board members in the U.S. market.

Stakeholder Impact

• Shareholders may experience minor dilution upon the vesting of these units.

Next Steps

• Vesting of the 40,000 RSUs on June 5, 2027, or the date of the 2027 annual meeting of stockholders.

Key Dates

Keywords

Pulmonx, LUNG, Form 4, Insider Trading, Equity Grant, Director Compensation